Date de publication: 19 juin 2018
Promoteur – Intermédiaire Financier
NIGHTINGALE HEALTH OYLieu
Description
The project concerns investments into research and development (R&D) and related capital expenditure activities in the field of blood analysis, to provide solutions for chronic disease detection and prevention.
Objectifs
The proposed transaction will support further development of the promoter's blood analysis platform, enable to generate scientific evidence of clinical utility of the promoter's risk prediction panel and support achieving reimbursement in Europe.
Secteur(s)
- Services - Activités spécialisées, scientifiques et techniques
Montant BEI envisagé (montant approximatif)
EUR 20 million
Coût total (montant approximatif)
EUR 55 million
Aspects environnementaux
The project mainly concerns investments in R&D that are expected to be carried out in existing facilities already authorised for the same purpose and would therefore not require an environmental impact assessment (EIA) under Directive 2011/92/EU. Full environmental details will be verified during the appraisal.
Passation des marchés
The promoter is a private company not operating in the utilities sector and which does not have the status of a contracting authority. Thus, it is not covered by EU Directives on procurement. However, the promoter's procurement procedures are expected to be in line with EIB guidelines for private sector projects. The Bank's services will verify details during the project due diligence.
Statut
Signé - 26/07/2018
Clause de non-responsabilité
Avant d’être approuvés par le Conseil d’administration et avant la signature des prêts correspondants, les projets font l’objet d’une instruction et de négociations. Par conséquent, les informations et données fournies sur cette page sont indicatives.
Elles sont fournies à des fins de transparence uniquement et ne peuvent être considérées comme représentant la politique officielle de la BEI (voir également les notes explicatives).